Dendritic cell-based immunotherapy of prostate cancer: Immune monitoring of a phase II clinical trial

Cancer Research

Volumn 60, Issue 4, 2000, Pages 829-833

  Lodge, Patricia A ^a   Jones, Lori A ^a   Bader, Robert A ^a   Murphy, Gerald P ^b   Salgaller, Michael L ^a  

^a Northwest Biotherapeutics Inc   (United States)

^b PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; CYTOKINE RELEASE; DENDRITIC CELL; DRUG CYTOTOXICITY; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOCOMPETENCE; MAJOR CLINICAL STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE ACTIVATION;

ANTIGENS, SURFACE; CARBOXYPEPTIDASES; DENDRITIC CELLS; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOCOMPETENCE; IMMUNOTHERAPY, ADOPTIVE; INTERFERON TYPE II; MALE; PROSTATIC NEOPLASMS;

EID: 0034652619     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Burnet, F. M. The concept of immunological surveillance. Prog. Exp. Tumor. Res., 13: 1-27, 1970.
2. Van den Eynde, B. J., and Boon, T. Tumor antigens recognized by T lymphocytes. Int. J. Clin. Lab. Res., 27: 81-86, 1997.
3. Rosenberg, S. A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity, 10: 281-287. 1999.
4. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y. S., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
5. Rosenberg, S. A., Yang, J. C. Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peplide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
6. Salgaller, M. L., and Lodge, P. A. Use of cellular and cytokine adjuvants in the immunotherapy of cancer. J. Surg. Oncol., 68: 122-138, 1998.
7. Hennemann, B., Beckmann, G., Eichelmann, A., Rehm, A., and Andreesen, R. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon γ and lipopolysaccharide. Cancer Immunol. Immunother., 45: 250-256, 1998.
8. Brodie, S. J., Lewinsohn, D. A., Patterson, B. K., Jiyamapa, D., Krieger, J., Corey, L., Greenberg, P. D., and Riddell, S. R. In vivo migration and function of transferred HIV-1-specific cytotoxic T cells. Nat. Med., 5: 34-41, 1999.
9. Kipps, T., and Mendoza, R. Extending genetic vaccines with chemokines. Nat. Biotechnol., 17: 226-227, 1999.
10. Salgaller, M. L. Monitoring of cancer patients undergoing active or passive immunotherapy, J. Immunother., 20: 1-14, 1997.
11. Romero, P., Cerottini, J. C., and Waanders, G. A. Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy. Mol. Med. Today, 4: 305-312, 1998.
12. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Troychak, M. J., Salgaller, M. L., and Boynton, A. L. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate, 39: 54-59, 1999.
13. Tjoa, B. A., Simmons, S. J., Elgamal, A., Rogers, M., Ragde, H., Kenny, G. M., Troychak, M. J., Boynton, A. L., and Murphy, G. P. Follow-up evaluation of a Phase II prostate cancer vaccine trial. Prostate, 40: 125-129, 1999.
14. Murphy, G. P., Tjoa, B. A., Simmons, S. J., Jarisch, J., Bowes, V. A., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Cobb, O. E., Ireton, R. C., Troychak, M. J., Salgaller, M. L., and Boynton, A. L. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate, 38: 73-78, 1999.
15. Utz, U., Koenig, S., Coligan, J. E., and Biddison, W. E. Presentation of three different viral peptides, HTLV-1 TAX, HCMV gB, and influenza virus MI, is determined by common structural features of the HLA-A2.1 molecule. J. Immunol., 149: 214-221, 1992.
16. Murphy, G., Tjoa, B., Ragde, H., Kenny, G., and Boynton, A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 29: 371-380, 1996.
17. Tjoa, B. A., Simmons, S. J., Bowes, V. A., Ragde, H., Rogers, M., Elgamal, A., Kenny, G. M., Cobb, O. E., Ireton, R. C., Troychak, M. J., Salgaller, M. L., Boynton, A. L., and Murphy, G. P. Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate, 36: 39-44, 1998.
18. Elgamal, A. A., Troychak, M. J., and Murphy, G. P. ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: analysis of 136 scans of 100 patients. Prostate, 37: 261-269, 1998.
19. Murphy, G. P., and Slack, N. H. Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate, 1: 375-382, 1980.
20. Fernandez, N. C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Perricaudet, M., Tursz, T. Maraskovsky, E., and Zitvogel, L. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med., 5: 405-411, 1999.
21. Restifo, N. P., Esquivel, F., Kawakami, Y., Yewdell, J. W., Mulθ, J. J., Rosenberg, S. A., and Bennick, J. R. Identification of human cancers deficient in antigen processing. J. Exp. Med., 177: 265-272, 1993.
22. Bodmer, W. F., Browning, M. J., Krausa, P., Rowan, A., Bicknell, D. C., and Bodmer, J. G. Tumor escape from immune response by variation in HLA expression and other mechanisms. Ann. NY Acad. Sci., 690: 42-49, 1993.
23. Hicklin, D. J., Marincola, F. M., and Ferrone, S. HLA class 1 antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today, 5: 178-186, 1999.
24. Sanda, M. G., Restifo, N. P., Walsh, J. C., Kawakami, Y., Nelson, W. G., Pardoll, D. M., and Simons, J. W. Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst., 87: 280-285, 1995.
25. Blades, R. A., Keating, P. J., McWilliam, L. J., George, N. J., and Stern, P. L. Loss of HLA class 1 expression in prostate cancer: implications for immunotherapy. Urology, 46: 681-686, 1995.